Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) Announces $80 Million Underwritten Offering and Insider Stock Purchase”

Recently, Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a pioneering radiopharmaceutical company specializing in advanced cancer treatments, announced the pricing of an underwritten offering of 51,515,880 shares of its common stock at $1.51 per share. Additionally, the company is offering pre-funded warrants to purchase 1,464,252 shares of common stock at $1.509 per pre-funded warrant. The total expected gross proceeds from this offering are approximately $80 million, before deducting underwriting discounts, commissions, and other expenses.

Details of the Offering

The offering is scheduled to close on or around May 29, 2024, subject to customary closing conditions. BofA Securities, Inc., Oppenheimer & Co. Inc., and RBC Capital Markets, LLC are acting as joint book-running managers for the offering, with B. Riley Securities, Inc. serving as co-manager.

All shares of common stock and pre-funded warrants are being sold by Perspective. The purchase price per share for each pre-funded warrant reflects the per-share offering price for the common stock, minus the $0.001 per share exercise price of such pre-funded warrant.

Use of Proceeds

Perspective intends to utilize the net proceeds from this offering for several key initiatives:

  1. Clinical Development: Continued development of VMT-α-NET, VMT-01/02, and PSV359.
  2. Preclinical Development: Further development of PSV40X and additional preclinical product candidates, alongside broader development platforms.
  3. Manufacturing Expansion: Building out, operating, and expanding manufacturing facilities.
  4. Corporate Purposes: Working capital and other general corporate needs.
  5. Potential Acquisitions: Although there are no current commitments, a portion of the proceeds may be used to acquire, license, or invest in complementary products, technologies, intellectual property, or businesses.

Insider Trading Activity

Recent insider trading activity includes a notable transaction by Director Robert F. Williamson III. On May 29, 2024, Williamson purchased 30,031 shares at a cost of $1.33 per share, totaling $40,014. This transaction brought Williamson’s total shares to 368,792. The details of this transaction were filed with the SEC on May 30, 2024, at 04:05 PM.

Registration and Offering Documents

The securities are being offered under an automatic shelf registration statement on Form S-3, effective upon filing with the Securities and Exchange Commission (SEC) on May 24, 2024. A final prospectus supplement will be filed with the SEC and will be accessible on the SEC’s website.

Investors can obtain copies of the final prospectus supplement and accompanying prospectus, when available, from BofA Securities, Inc., Oppenheimer & Co. Inc., and RBC Capital Markets, LLC. Contact details for these institutions are provided in the company’s press release.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is at the forefront of radiopharmaceutical development, creating advanced treatment applications for cancers throughout the body. The company leverages proprietary technology using the alpha-emitting isotope 212Pb, delivering potent radiation directly to cancer cells through specialized targeting peptides. This approach, known as “theranostics,” combines therapeutic and diagnostic capabilities to personalize treatment and optimize patient outcomes.

The company’s programs, including those targeting melanoma (VMT01) and neuroendocrine tumors (VMT-α-NET), are in Phase 1/2a imaging and therapy trials at leading academic institutions. Perspective Therapeutics also boasts a proprietary 212Pb generator, ensuring a reliable supply of key isotopes for both clinical trials and commercial operations.


Perspective Therapeutics, Inc.’s recent underwritten offering marks a significant step in its journey towards advancing cancer treatment. With substantial funding secured, the company is well-positioned to continue its innovative work in radiopharmaceuticals and improve outcomes for cancer patients.